Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubham Pant

Showing results (81-90 of 181) with videos related to

Pageof 19
Sort By:
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional AnalysisSunyoung S Lee, Dong Hyun Seo, Taek Chung, et al.
British Journal of Haematology|October 14, 2009
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemiaShubham Pant, Mehdi Hamadani, Anthony J Dodds, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Cancer Chemotherapy and Pharmacology|June 26, 2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesMaryam B Lustberg, Shubham Pant, Amy S Ruppert, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Eclinicalmedicine|April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumorsGerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
Pageof 19

Showing results (81-90 of 181) with videos related to

Sort By:
Pageof 19
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional AnalysisSunyoung S Lee, Dong Hyun Seo, Taek Chung, et al.
British Journal of Haematology|October 14, 2009
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemiaShubham Pant, Mehdi Hamadani, Anthony J Dodds, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Cancer Chemotherapy and Pharmacology|June 26, 2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesMaryam B Lustberg, Shubham Pant, Amy S Ruppert, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Eclinicalmedicine|April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumorsGerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
Pageof 19